Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-6 aGVHD Siltuximab
2024-510924-38-00Phase 2Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of siltuximab in graft-versus-host disease (GVHD), sponsored by University Medical Center Groningen. Planned start Feb 2025; status: authorised.
02
Drugs
siltuximab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on 2024-510924-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510924-38-00.